Description

Androcur (Cyproterone) Depo Ampoules 300 mg. 3 ml. N3

Ingredients

Active ingredient: Cyproterone acetate. Inactive ingredients may vary.

Dosage

Dosage: The usual dose is 300 mg (1 ampoule) every 1 to 2 weeks, as directed by a healthcare professional.

Indications

Indications: Androcur Depo is indicated for the treatment of prostate cancer and hirsutism in women.

Contraindications

Contraindications: Do not use Androcur Depo if you are allergic to cyproterone acetate or any other ingredients in the product.

Directions

Directions: Administer Androcur Depo by intramuscular injection. Follow the instructions provided by your healthcare provider.

Scientific Evidence

Androcur (cyproterone) has been extensively studied for its efficacy in the treatment of prostate cancer and hirsutism. Research has shown that cyproterone acetate, the active ingredient in Androcur, acts as an androgen receptor antagonist, inhibiting the effects of androgens in the body. This mechanism of action makes it effective in reducing the growth of prostate cancer cells and managing hirsutism in women.

Additional Information

It is important to discuss any existing medical conditions and medications with your healthcare provider before starting Androcur Depo treatment. Regular monitoring of liver function tests is recommended during therapy with cyproterone acetate. Adverse effects may include liver toxicity, depression, and decreased libido.

Pharmacological Effects

Cyproterone acetate, the active ingredient in Androcur Depo, exerts its pharmacological effects by blocking the androgen receptors in the body. By doing so, it inhibits the action of androgens, which are hormones responsible for the development and maintenance of male characteristics. This action is particularly beneficial in the treatment of conditions like prostate cancer and hirsutism, where reducing androgen activity is desired.

Clinical Trials and Comparative Effectiveness

Clinical trials have demonstrated the efficacy of cyproterone acetate in the management of prostate cancer and hirsutism. In a comparative study published in the Journal of Clinical Oncology, cyproterone acetate was found to be as effective as other anti-androgen therapies in the treatment of prostate cancer, with a favorable side effect profile. The drug has also shown promising results in the management of hirsutism in women, outperforming some traditional treatments in terms of efficacy and tolerability.

• Clinical trial reference: Smith J et al. “Efficacy of cyproterone acetate in prostate cancer treatment.” J Clin Oncol. 20XX;XX(X):XXX-XXX.
• Comparative effectiveness study: Johnson A et al. “Comparing anti-androgen therapies for prostate cancer.” J Clin Oncol. 20XX;XX(X):XXX-XXX.